News

MEFOPA Annual Meeting
April 2012 Paris

Subproject 3

 

Objectives

 

In this subproject “Patient Registry and Biobanking”, the groundwork will be laid for future early phase II disease-modifying trials in patients with rare Mendelian forms of PD, by

  1. ascertaining the world-wide largest cohort of patients with rare Mendelian forms of PD, as well as their pre-symptomatic mutation-carrying relatives
  2. establishing a biobank with biological fluids (plasma, serum, CSF) and cells (lymphocytes, fibroblasts) from these patients for transcriptomic, proteomic and biochemical studies
  3. conducting longitudinal investigations of changes in these individuals on the transcriptomic and proteomic level, as well as by focused analysis of candidate proteins, in order to define suitable biomarkers as read-outs for rationally designed drug trials.

 

Workpackages

 

Workpackage No Work package title Lead Participant No Work Package
Leader
3.1 MEFOPA-Registry University of Tuebingen Thomas Gasser
3.2 MEFOPA-biobank University of Tuebingen Thomas Gasser
3.3 Transcpritional changes in ex vivo cells from patients with rare Mendelian forms of PD University of Tuebingen Olaf Riess
3.4 Proteomic changes in body fluids and  ex vivo cells from patients with rare Mendelian forms of PD Vrije Universiteit: Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patientenzorg Guus Smit
3.5 Determination of a-synuclein species in biological fluids United Arab Emirates University, Faculty of Medicine and Health Science Omar El-Agnaf
MA Management activities University of Tuebingen Holm Graessner